December 16, 2016

December 16, 2016

Researchers Aim to Refine Use of VEGF, EGFR Inhibitors in NSCLC OncLive – Dec. 14
In an interview during the 2016 OncLive State of the Science Summit on Advanced Non–Small Cell Lung Cancer, Alberto A. Chiappori, MD, a senior member in the Department of Thoracic Oncology at Moffitt Cancer Center, spoke on monoclonal antibodies targeting VEGF and EGFR, their benefits and limitations, and how he sees the field evolving.

CPX-351: Better Outcomes in Older High-Risk AML Patients
Medscape – Dec. 14
The CPX-351 liposomal formulation contains a fixed combination of cytarabine and daunorubicin in a 5:1 molar ratio that maximizes synergy. "The unique aspect of delivering these drugs together is that the synergistic ratio is maintained up to the point of delivery," presenter Jeffrey E. Lancet, MD, chair and program leader of the Malignant Hematology Department at the Moffitt Cancer Center, Tampa, Florida, told Medscape Medical News.

Innovation: Four scientists with USF ties named fellows in National Academy of Inventors
Tampa Bay Times – Dec. 13
Lawrence is a professor in the department of oncologic sciences at USF and a senior member of Moffitt Cancer Center's drug discovery department, where he has made important contributions in designing and synthesizing organic molecules to act as anticancer agents.

Dr. Nicholas Lawrence Earns A Place As A Fellow Of The 2016 NAI
Tampa Patch – Dec. 13
From Moffitt Cancer Center: Nicholas Lawrence, Ph.D., senior research faculty member at Moffitt Cancer Center, has been named a Fellow of the 2016 National Academy of Inventors (NAI).

USF inventors, alumnus join National Academy of Inventors
Tampa Bay Business Journal – Dec. 13
Also chosen were: Nicholas Lawrence, a professor in the USF department of oncologic sciences and a senior member of the drug discovery department at Moffitt Cancer Center. Lawrence’s work was instrumental in an agreement between Moffitt and Aptose Biosciences (NASDAQ: APTO) that is expected to help Aptose expand its pipeline for cancer-fighting therapies.

Health Data Security: A tipping point
Data Breach Today – Dec. 13
Has the healthcare sector finally reached a data security tipping point?Dave Summitt, CISO of H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., thinks so. And so do many of his peers.

New Chemotherapy Delivery Method Improves Survival After Bone Marrow Transplant in Older Acute Myeloid Leukemia Patients
Bioscience Technology – Dec. 12
“The two drugs together are delivered to the cell in the proper synergistic ratio that optimizes the cell-killing ability of these two drugs,” said lead study author Jeffrey E. Lancet, MD, of the Moffitt Cancer Center in Tampa, Fla. 

PARP inhibitory velaparib trialled in BRCA1/2 breast cancer
eCancer.org – Dec. 13
Dr Han speaks with ecancertv at SABCS 2016 about the outcomes from a trial of added velaparib to chemotherapy for BRCA1/2 mutant metastatic breast cancers.

Heather Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel
ASCO Post – Dec. 11
Heather Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).

Novel Compound Targets Anemia in MDS
MedPage Today – Dec. 9
In a phase II dose-ranging study, sotatercept (also known as ACE-011) led to hematological improvement in nearly half of 54 evaluable patients who did not respond to erythropoiesis-stimulating agents, according to Rami Komrokji, MD, of Moffitt Cancer Center in Tampa, Fla., and colleagues.

'Alive, Dead, or Somewhere in Between?' What We Heard This Week
MedPage Today – Dec. 9
"Induction with CPX-351 was associated with lower induction-related morbidity and mortality, which means that patients may be transplanted in better condition. Patients may also attain better disease control, leading to more patients being transplanted in complete remission." -- Jeffrey Lancet, MD, of Moffitt Cancer Center in Tampa, Fla., on data from a randomized trial of induction therapy with an investigational liposome-encapsulated chemotherapy prior to allogeneic stem cell transplant.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.